Document
IPR2023-00724, No. 1093 Exhibit - Beel Declaration (P.T.A.B. Dec. 18, 2023)
Cite Document
IPR2023-00724, No. 1093 Exhibit - Beel Declaration (P.T.A.B. Dec. 18, 2023)
+ More Snippets
Document
IPR2023-00724, No. 2539 Exhibit - EX2539 Notice of Service, In re Ozempic Semaglutide Patent Litigation, No 122 md 03038 CFC Dkt 330 (P.T.A.B. Jul. 31, 2024)
Cite Document
IPR2023-00724, No. 2539 Exhibit - EX2539 Notice of Service, In re Ozempic Semaglutide Patent Litigation, No 122 md 03038 CFC Dkt 330 (P.T.A.B. Jul. 31, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2650 Exhibit - EX2650 Excerpt of Reply Expert Report of Dr John Bantle Regarding In validity of US Patent No 10,335,462, In re Ozempic Semag lutide Patent Litigation, No 122 cv 03
Cite Document
IPR2023-00724, No. 2650 Exhibit - EX2650 Excerpt of Reply Expert Report of Dr John Bantle Regarding In validity of US Patent No 10,335,462, In re Ozempic Semag lutide Patent Litigation, No 122 cv 03
+ More Snippets
Document
IPR2023-00724, No. 2090 Exhibit - EX2090 Cosentino, F et al, ESC Guidelines on diabetes, pre diabetes, and cardiovascular diseases developed in collaboration with the EASD, Eur Heart J, 41...
Cite Document
IPR2023-00724, No. 2090 Exhibit - EX2090 Cosentino, F et al, ESC Guidelines on diabetes, pre diabetes, and cardiovascular diseases developed in collaboration with the EASD, Eur Heart J, 41255 323 20
+ More Snippets
Document
IPR2023-00724, No. 2368 Exhibit - EX2368 Tomkin, GH, Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors, World J Diabetes, 2014 Oct 15 55636 650 (P.T.A.B. Jan. 17...
Cite Document
IPR2023-00724, No. 2368 Exhibit - EX2368 Tomkin, GH, Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors, World J Diabetes, 2014 Oct 15 55636 650 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2017 Exhibit - EX2017 Novo Nordisk Company Announcement October 10, 2023 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2017 Exhibit - EX2017 Novo Nordisk Company Announcement October 10, 2023 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2460 Exhibit - EX2460 US Food Drug Administration, DrugsFDA, Xultophy 10036 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2460 Exhibit - EX2460 US Food Drug Administration, DrugsFDA, Xultophy 10036 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1048 Exhibit - FDA Exposure Response 2003 (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1048 Exhibit - FDA Exposure Response 2003 (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 2415 Exhibit - EX2415 US Food Drug Administration, DrugsFDA, Tradjenta® (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2415 Exhibit - EX2415 US Food Drug Administration, DrugsFDA, Tradjenta® (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1114 Exhibit - Exhibit 1114 Buse (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1114 Exhibit - Exhibit 1114 Buse (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1130 Exhibit - Exhibit 1130 Novo Nordisk Annual Report 2011 (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1130 Exhibit - Exhibit 1130 Novo Nordisk Annual Report 2011 (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1135 Exhibit - Exhibit 1135 40th Orange Book (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1135 Exhibit - Exhibit 1135 40th Orange Book (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2470 Exhibit - EX2470 Rybelsus Prescribing Information rev Jan 2020 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2470 Exhibit - EX2470 Rybelsus Prescribing Information rev Jan 2020 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2654 Exhibit - EX2654 July 10, 2024 Email Thread Among Counsel for Petitioners Mylan, DRL, and Sun, and Counsel for Novo Regarding IPR2023 00724 – Service of draft ...
Cite Document
IPR2023-00724, No. 2654 Exhibit - EX2654 July 10, 2024 Email Thread Among Counsel for Petitioners Mylan, DRL, and Sun, and Counsel for Novo Regarding IPR2023 00724 – Service of draft proposed motion
+ More Snippets
Document
IPR2023-00724, No. 1088 Exhibit - Exhibit 1088 (P.T.A.B. Aug. 10, 2023)
Cite Document
IPR2023-00724, No. 1088 Exhibit - Exhibit 1088 (P.T.A.B. Aug. 10, 2023)
+ More Snippets